TP53 and leukemia: It shows promise for treating leukemia that has an acquired resistance to apoptosis, including in p53 knockout cells and in cells treated with anti-apoptotic agents (Bots et al., 2014) and which can play a role in controlling the cell cycle (Chiron et al., 2013).